I 
108TH CONGRESS 
2D SESSION 
H. R. 3866
To amend the Controlled Substances Act to provide increased penalties for 
anabolic steroid offenses near sports facilities, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 1, 2004
Mr. SENSENBRENNER (for himself, Mr. CONYERS, Mr. SWEENEY, Mr. 
OSBORNE, and Mr. BERMAN) introduced the following bill; which was re-
ferred to the Committee on the Judiciary, and in addition to the Com-
mittee on Energy and Commerce, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
A BILL 
To amend the Controlled Substances Act to provide increased 
penalties for anabolic steroid offenses near sports facili-
ties, and for other purposes.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Anabolic Steroid Con-
trol Act of 2004’’.
SEC. 2. INCREASED PENALTIES FOR ANABOLIC STEROID 
OFFENSES NEAR SPORTS FACILITIES. 
(a) IN GENERAL.—Part D of the Controlled Sub-
stances Act is amended by adding at the end the following: 
ANABOLIC STEROID OFFENSES NEAR SPORTS FACILITIES 
‘‘SEC. 424. (a) Whoever violates section 401(a)(1) or 
section 416 by manufacturing, distributing, or possessing 
with intent to distribute, an anabolic steroid near or at 
a sports facility is subject to twice the maximum term of 
imprisonment, maximum fine, and maximum term of su-
pervised release otherwise provided by section 401 for that 
offense. 
‘‘(b) As used in this section—
‘‘(1) the term ‘sports facility’ means real prop-
erty where athletic sports or athletic training takes 
place, if such property is privately owned for com-
mercial purposes or if such property is publicly 
owned, but does not include any real property de-
scribed in section 419; 
‘‘(2) the term ‘near or at’ means in or on, or 
within 1000 feet of; and 
‘‘(3) the term ‘possessing with intent to dis-
tribute’ means possessing with the intent to dis-
tribute near or at a sports facility.’’. 
(b) TABLE OF CONTENTS AMENDMENT.—The table 
of contents for Comprehensive Drug Abuse Prevention
and Control Act of 1970 is amended by inserting after 
the item relating to section 423 the following new item:
‘‘424. Increased Penalties for Anabolic Steroid Offenses Near Sports Facili-
ties.’’.
SEC. 3. SENTENCING COMMISSION GUIDELINES. 
The United States Sentencing Commission shall—
(1) review the Federal sentencing guidelines 
with respect to offenses involving anabolic steroids; 
(2) consider amending the Federal sentencing 
guidelines to provide for increased penalties with re-
spect to offenses involving anabolic steroids in a 
manner that reflects the seriousness of such offenses 
and the need to deter anabolic steroid use; and 
(3) take such other action that the Commission 
considers necessary to carry out this section. 
SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) DEFINITIONS.—Section 102 of the Controlled 
Substances Act (21 U.S.C. 802) is amended—
(1) in paragraph (41)—
(A) by realigning the margin so as to align 
with paragraph (40); and 
(B) by striking subparagraph (A) and in-
serting the following: 
‘‘(A) The term ‘anabolic steroid’ means any drug or 
hormonal substance, chemically and pharmacologically re-
lated to testosterone (other than estrogens, progestins, 
corticosteroids, and dehydroepiandrosterone), and in-
cludes—
‘‘(i) androstanediol—
‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 
‘‘(II) 3α,17β-dihydroxy-5α-androstane; 
‘‘(ii) 
androstanedione 
(5α-androstan-3,17-
dione); 
‘‘(iii) androstenediol—
‘‘(I) 1-androstenediol (3β,17β-dihydroxy-
5α-androst-1-ene); 
‘‘(II) 1-androstenediol (3α,17β-dihydroxy-
5α-androst-1-ene); 
‘‘(III) 4-androstenediol (3β,17β-dihydroxy-
androst-4-ene); and 
‘‘(IV) 5-androstenediol (3b,17β-dihydroxy-
androst-5-ene); 
‘‘(iv) androstenedione—
‘‘(I) 1-androstenedione ([5α]-androst-1-en-
3,17-dione); 
‘‘(II) 
4-androstenedione 
(androst-4-en-
3,17-dione); and 
‘‘(III) 
5-androstenedione 
(androst-5-en-
3,17-dione);
‘‘(xvii) 4-hydroxytestosterone (4,17β-dihydroxy-
androst-4-en-3-one); 
‘‘(xviii) 4-hydroxy-19-nortestosterone (4,17β-
dihydroxy-estr-4-en-3-one); 
‘‘(xix) mestanolone (17α-methyl-17β-hydroxy-
5α-androstan-3-one); 
‘‘(xx) 
mesterolone 
(1α-methyl-17β-hydroxy-
[5α]-androstan-3-one); 
‘‘(xxi) 
methandienone 
(17α-methyl-17β-
hydroxyandrost-1,4-dien-3-one); 
‘‘(xxii) 
methandriol 
(17α-methyl-3β,17β-
dihydroxyandrost-5-ene); 
‘‘(xxiii) methenolone (1-methyl-17β-hydroxy-5α-
androst-1-en-3-one); 
‘‘(xxiv) 
methyltestosterone 
(17α-methyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(xxv) 
mibolerone 
(7α,17α-dimethyl-17β-
hydroxyestr-4-en-3-one); 
‘‘(xxvi) 
nandrolone 
(17β-hydroxyestr-4-en-3-
one); 
‘‘(xxvii) norandrostenediol—
‘‘(I) 19-nor-4-androstenediol (3β, 17β-
dihydroxyestr-4-ene); 
‘‘(II) 19-nor-4-androstenediol (3α, 17β-
dihydroxyestr-4-ene);
‘‘(III) 19-nor-5-androstenediol (3β, 17β-
dihydroxyestr-5-ene); and 
‘‘(IV) 19-nor-5-androstenediol (3α, 17β-
dihydroxyestr-5-ene); 
‘‘(xxviii) norandrostenedione—
‘‘(I) 19-nor-4-androstenedione (estr-4-en-
3,17-dione); and 
‘‘(II) 19-nor-5-androstenedione (estr-5-en-
3,17-dione; 
‘‘(xxix) 
norbolethone 
(18α-homo-17β-
hydroxypregna-4-en-3-one); 
‘‘(xxx) norclostebol (4-chloro-17β-hydroxyestr-4-
en-3-one); 
‘‘(xxxi) 
norethandrolone 
(17α-ethyl-17β-
hydroxyestr-4-en-3-one); 
‘‘(xxxii) oxandrolone (17α-methyl-17β-hydroxy-
2-oxa-[5α]-androstan-3-one);
‘‘(xxxiii) 
oxymesterone 
(17α-methyl-4,17β-
dihydroxyandrost-4-en-3-one); 
‘‘(xxxiv) 
oxymetholone 
(17α-methyl-2-
hydroxymethylene-17β-hydroxy-[5α]-androstan-3-
one); 
‘‘(xxxv) stanozolol (17α-methyl-17β-hydroxy-
[5α]-androst-2-eno[3,2-c]-pyrazole);
‘‘(xxxvi) 
stenbolone 
(17β-hydroxy-2-methyl-
[5α]-androst-1-en-3-one); 
‘‘(xxxvii) testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic acid lactone); 
‘‘(xxxviii) 
1-testosterone 
(17β-hydroxy-5α-
androst-1-en-3-one); 
‘‘(xxxix) testosterone (17β-hydroxyandrost-4-en-
3-one); 
‘‘(xl) 
tetrahydrogestrinone 
(13β,17α-diethyl-
17β-hydroxygon-4,9,11-trien-3-one); 
‘‘(xli) trenbolone (17β-hydroxyestr-4,9,11-trien-
3-one); and 
‘‘(xlii) any salt, ester, or ether of a drug or sub-
stance described in this paragraph.’’; and 
(2) in paragraph (44), by inserting ‘‘anabolic 
steroids,’’ after ‘‘marihuana,’’. 
(b) AUTHORITY
AND CRITERIA
FOR CLASSIFICA-
TION.—Section 201(g) of the Controlled Substances Act 
(21 U.S.C. 811(g)) is amended—
(1) in paragraph (1), by striking ‘‘substance 
from a schedule if such substance’’ and inserting 
‘‘drug which contains a controlled substance from 
the application of titles II and III of the Comprehen-
sive Drug Abuse Prevention and Control Act (21 
U.S.C. 802 et seq.) if such drug’’; and
(2) in paragraph (3), by adding at the end the 
following: 
‘‘(C) Upon the recommendation of the Sec-
retary of Health and Human Services, a compound, 
mixture, or preparation which contains any anabolic 
steroid, which is intended for administration to a 
human being or an animal, and which, because of its 
concentration, preparation, formulation or delivery 
system, does not present any significant potential for 
abuse.’’.
Æ